FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE
Peakfluorescein sodium and benoxinate hydrochloride
NDAOPHTHALMICSOLUTION/DROPS
Approved
Mar 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE (fluorescein sodium and benoxinate hydrochloride) by Bausch + Lomb is 12. First approved in 2020.
Drug data last refreshed 26m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Fluorescein sodium and benoxinate hydrochloride is a topical ophthalmic solution combining a diagnostic dye and local anesthetic for corneal procedures. The benoxinate component provides rapid local anesthesia (onset 5-45 seconds, duration ~20 minutes) while fluorescein enables visualization during ophthalmic examination and intervention. This fixed combination is administered as eye drops for diagnostic and minor surgical ophthalmic procedures.
Peak11.0 years to LOE
Product is in peak commercial phase with established market presence in ophthalmic settings; commercial teams are likely maintaining market position rather than scaling aggressively.
Mechanism of Action
12.2 Pharmacodynamics Maximal corneal anesthesia usually occurs in about 5-45 seconds and lasts about 20 minutes after single administration. The anesthetic effect may be extended by subsequent administration 10-20 minutes after the last administration.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This is a niche, established ophthalmic specialty product with minimal linked job openings, reflecting its mature lifecycle and focused market. Roles are concentrated in commercial execution and account management within ophthalmology channels rather than in growth-phase hiring.
Brand Manager
Worked on FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.